SCHEMBL3605749

SCHEMBL3605749

CN(C(=O)O)C1CCN(CCCc2cc(-c3ccc(Cl)cc3)on2)CC1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
CXCR1 P25024 1/20 0.43
CCR5 P51681 1/20 0.42
POLB P06746 2/20 0.42
MAPT P10636 2/20 0.42
MCHR1 Q99705 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
CYP2D6 P10635 2/20 0.40
CYP1A2 P05177 1/20 0.40
GAA P10253 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
S1PR1 P21453 1/20 0.40
C5AR1 P21730 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594728 0.94 NOTUM (0.45) NOTUMNPC1RAB9ADRD2DRD4
SCHEMBL3594360 0.83 DRD2 (0.45) NOTUMDRD2DRD4DRD3CXCR1
SCHEMBL3605744 0.80 HIF1A (0.44) NOTUMNPC1RAB9ADRD2DRD4
SCHEMBL5486911 0.80 NOTUM (0.50) NOTUMNPC1RAB9ACXCR1POLB
SCHEMBL2981434 0.80 POLB (0.41) NOTUMNPC1RAB9ADRD2DRD4
SCHEMBL3593612 0.79 DRD4 (0.47) NOTUMNPC1RAB9ADRD2DRD4
SCHEMBL5709441 0.79 MAPT (0.45) NOTUMNPC1RAB9ADRD2DRD4
SCHEMBL2981437 0.78 MAPT (0.39) NOTUMNPC1RAB9ADRD2DRD4
SCHEMBL2981428 0.77 MAPT (0.43) NOTUMNPC1RAB9ADRD2DRD4
SCHEMBL3606182 0.75 DRD2 (0.51) NOTUMNPC1RAB9ADRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP claimed
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2010-11-04 US disclosed
EP-1720550-B1 DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2009-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100279998-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 NOTUM 47/4885NPC1 441/4885RAB9A 2114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.